Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Current Topics in Behavioral Neurosciences
|
December 24, 2015
Misuse of Methylphenidate
David B Clemow
Postgraduate Medicine
|
November 26, 2014
Suboptimal dosing of Strattera (atomoxetine) for ADHD patients
David B Clemow
Inflammatory Bowel Diseases
|
April 16, 2026
Response to: The Long Game in Ulcerative Colitis: Mirikizumab's Four-Year Outcomes
David B Clemow
Journal of Psychopharmacology (Oxford, England)
|
September 10, 2015
Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients
David B Clemow, Chris J Bushe
Postgraduate Medicine
|
October 9, 2014
The potential for misuse and abuse of medications in ADHD: a review
David B Clemow, Daniel J Walker
CNS Neuroscience & Therapeutics
|
August 2, 2016
Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder
David B Clemow, Allen W Nyhuis, Rebecca L Robinson
The Journal of Clinical Psychiatry
|
January 20, 2006
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder
Scott W Andersen, David B Clemow, Sara A Corya
Postgraduate Medicine
|
September 8, 2015
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder
Daniel J Walker, Oren Mason, David B Clemow, et al.
Pain Practice : the Official Journal of World Institute of Pain
|
October 25, 2013
Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc Analysis
Robert J Tanenberg, David B Clemow, Joseph M Giaconia, et al.
Current Medical Research and Opinion
|
August 14, 2020
Lasmiditan in patients with common migraine comorbidities: a <i>post hoc</i> efficacy and safety analysis of two phase 3 randomized clinical trials
David B Clemow, Simin K Baygani, Paula M Hauck, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Current Topics in Behavioral Neurosciences
|
December 24, 2015
Misuse of Methylphenidate
David B Clemow
Postgraduate Medicine
|
November 26, 2014
Suboptimal dosing of Strattera (atomoxetine) for ADHD patients
David B Clemow
Inflammatory Bowel Diseases
|
April 16, 2026
Response to: The Long Game in Ulcerative Colitis: Mirikizumab's Four-Year Outcomes
David B Clemow
Journal of Psychopharmacology (Oxford, England)
|
September 10, 2015
Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients
David B Clemow, Chris J Bushe
Postgraduate Medicine
|
October 9, 2014
The potential for misuse and abuse of medications in ADHD: a review
David B Clemow, Daniel J Walker
CNS Neuroscience & Therapeutics
|
August 2, 2016
Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder
David B Clemow, Allen W Nyhuis, Rebecca L Robinson
The Journal of Clinical Psychiatry
|
January 20, 2006
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder
Scott W Andersen, David B Clemow, Sara A Corya
Postgraduate Medicine
|
September 8, 2015
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder
Daniel J Walker, Oren Mason, David B Clemow, et al.
Pain Practice : the Official Journal of World Institute of Pain
|
October 25, 2013
Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc Analysis
Robert J Tanenberg, David B Clemow, Joseph M Giaconia, et al.
Current Medical Research and Opinion
|
August 14, 2020
Lasmiditan in patients with common migraine comorbidities: a <i>post hoc</i> efficacy and safety analysis of two phase 3 randomized clinical trials
David B Clemow, Simin K Baygani, Paula M Hauck, et al.
Page
of 3